Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Artrya Limited ( (AU:AYA) ) has shared an announcement.
Artrya Limited announced that its Co-Founder and CEO, John Konstantopoulos, will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. This event, which gathers industry leaders and investors, provides Artrya with an opportunity to showcase its AI-powered platform for coronary artery disease assessment, potentially enhancing its visibility and positioning in the medical technology sector.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company specializing in AI-powered solutions for the detection and management of coronary artery disease. The company’s proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in diagnosing patients more accurately and efficiently. Artrya is focused on advancing cardiac care through innovative technology, with ongoing regulatory and commercial activities in key international markets.
Average Trading Volume: 1,030,691
Technical Sentiment Signal: Buy
Current Market Cap: A$564.4M
See more insights into AYA stock on TipRanks’ Stock Analysis page.